Advertisement

Topics

Another Week, Another Gene Therapy Buyout: Catalent Pays $1.2B for Paragon

08:10 EDT 15 Apr 2019 | Xconomy

The gene therapy boom continued this morning with yet another acquisition. Contract drug manufacturer Catalent (NYSE: CTLT), of Somerset, NJ, has agreed to buy Paragon Bioservices for $1.2 billion, grabbing hold of a privately held developer of the viral “vectors” that gene therapy companies use to deliver their treatments. In a gene therapy procedure, these […]

Original Article: Another Week, Another Gene Therapy Buyout: Catalent Pays $1.2B for Paragon

NEXT ARTICLE

More From BioPortfolio on "Another Week, Another Gene Therapy Buyout: Catalent Pays $1.2B for Paragon"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...